,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'lba3 ']
dr. modi lba3 #asco22: bottom line, benefits of t-dxd seen in all subgroups of her2 mbc, and the os advantage should make this practice-changing per dr. modi 
Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi